143 related articles for article (PubMed ID: 8746921)
1. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing.
Johnson RE; Eissenberg T; Stitzer ML; Strain EC; Liebson IA; Bigelow GE
Drug Alcohol Depend; 1995 Nov; 40(1):27-35. PubMed ID: 8746921
[TBL] [Abstract][Full Text] [Related]
2. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence.
Johnson RE; Eissenberg T; Stitzer ML; Strain EC; Liebson IA; Bigelow GE
Drug Alcohol Depend; 1995 Nov; 40(1):17-25. PubMed ID: 8746920
[TBL] [Abstract][Full Text] [Related]
3. Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects.
San L; Camí J; Fernández T; Ollé JM; Peri JM; Torrens M
Br J Addict; 1992 Jan; 87(1):55-62. PubMed ID: 1311974
[TBL] [Abstract][Full Text] [Related]
4. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.
Kuhlman JJ; Levine B; Johnson RE; Fudala PJ; Cone EJ
Addiction; 1998 Apr; 93(4):549-59. PubMed ID: 9684393
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
Strain EC; Stitzer ML; Liebson IA; Bigelow GE
J Clin Psychopharmacol; 1996 Feb; 16(1):58-67. PubMed ID: 8834420
[TBL] [Abstract][Full Text] [Related]
6. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans.
Amass L; Bickel WK; Crean JP; Blake J; Higgins ST
Psychopharmacology (Berl); 1998 Apr; 136(3):217-25. PubMed ID: 9566806
[TBL] [Abstract][Full Text] [Related]
7. Thrice-weekly versus daily buprenorphine maintenance.
Schottenfeld RS; Pakes J; O'Connor P; Chawarski M; Oliveto A; Kosten TR
Biol Psychiatry; 2000 Jun; 47(12):1072-9. PubMed ID: 10862807
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients.
Mattick RP; Ali R; White JM; O'Brien S; Wolk S; Danz C
Addiction; 2003 Apr; 98(4):441-52. PubMed ID: 12653814
[TBL] [Abstract][Full Text] [Related]
10. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence.
Ling W; Wesson DR; Charuvastra C; Klett CJ
Arch Gen Psychiatry; 1996 May; 53(5):401-7. PubMed ID: 8624183
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence.
Montoya ID; Gorelick DA; Preston KL; Schroeder JR; Umbricht A; Cheskin LJ; Lange WR; Contoreggi C; Johnson RE; Fudala PJ
Clin Pharmacol Ther; 2004 Jan; 75(1):34-48. PubMed ID: 14749690
[TBL] [Abstract][Full Text] [Related]
12. Alternate-day dosing during buprenorphine treatment of opioid dependence.
Amass L; Bickel WK; Higgins ST; Badger GJ
Life Sci; 1994; 54(17):1215-28. PubMed ID: 8164503
[TBL] [Abstract][Full Text] [Related]
13. Short-term buprenorphine maintenance: treatment outcome.
Galanter M; Dermatis H; Resnick R; Maslansky R; Neumann E
J Addict Dis; 2003; 22(3):39-49. PubMed ID: 14621343
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.
Amass L; Kamien JB; Mikulich SK
Drug Alcohol Depend; 2000 Feb; 58(1-2):143-52. PubMed ID: 10669065
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic.
O'Connor PG; Oliveto AH; Shi JM; Triffleman EG; Carroll KM; Kosten TR; Rounsaville BJ; Pakes JA; Schottenfeld RS
Am J Med; 1998 Aug; 105(2):100-5. PubMed ID: 9727815
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence.
Pérez de los Cobos J; Martin S; Etcheberrigaray A; Trujols J; Batlle F; Tejero A; Queraltó JM; Casas M
Drug Alcohol Depend; 2000 Jun; 59(3):223-33. PubMed ID: 10812283
[TBL] [Abstract][Full Text] [Related]
18. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
[TBL] [Abstract][Full Text] [Related]
19. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
[TBL] [Abstract][Full Text] [Related]
20. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.
Umbricht A; Hoover DR; Tucker MJ; Leslie JM; Chaisson RE; Preston KL
Drug Alcohol Depend; 2003 Apr; 69(3):263-72. PubMed ID: 12633912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
